睿知中国医院研究地图
候选清单

正在招募肺癌乳腺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of GC203 TIL in Advanced Malignant Solid Tumors

ClinicalTrials.gov 上登记的一项肺癌和乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06375187,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients must be ≥18 and ≤75 years of age at the time of consent. 3. Patients with advanced metastatic solid tumors with clear pathological diagnosis have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy [including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery]) , including but not limited to gynecological tumors (ovarian cancer, endometrial cancer, cervical cancer), breast cancer, gastrointestinal Cancer, lung cancer.

    入选标准第 2 条

  3. Patients have feasible tissue areas for tumor resection/puncture to generate GC203 TIL, the total volume of the tissue > 400mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency therapy, oncolytic virus, etc.) or has progressed after local treatment; 5. At least one measurable target lesion before preconditioning, as defined by RECIST1.1.

    入选标准第 3 条

    Total Bilirubin(TBIL)≤1.5×ULN; 9. Women of child-bearing potential (WCBP), must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.

    入选标准第 15 条

    Patients who have received systemic antitumor therapy within 4 weeks.

    排除标准第 3 条

  4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    入选标准第 4 条

  5. Absolute Neutrophil Count (ANC)≥1.0×10\^9/L;

    入选标准第 6 条

    Platelet≥80×10\^9/L;

    入选标准第 8 条

    International Normalized Ratio(INR)≤1.5×ULN;

    入选标准第 9 条

    Activated Partial Thromboplastin Time(APTT)≤1.5×ULN;

    入选标准第 10 条

    Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min

    入选标准第 11 条

    Alanine aminotransferase(AST/SGOT) ≤3×ULN;

    入选标准第 13 条

    Alanine aminotransferase (ALT/SGPT) ≤3×ULN;

    入选标准第 14 条

  6. Patients who have had another primary malignancy within the previous 5 years

    排除标准第 4 条

  7. Patients who are pregnant or breastfeeding.

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06375187,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.
  2. Patients must be ≥18 and ≤75 years of age at the time of consent. 3. Patients with advanced metastatic solid tumors with clear pathological diagnosis have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy [including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery]) , including but not limited to gynecological tumors (ovarian cancer, endometrial cancer, cervical cancer), breast cancer, gastrointestinal Cancer, lung cancer.
  3. Patients have feasible tissue areas for tumor resection/puncture to generate GC203 TIL, the total volume of the tissue > 400mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency therapy, oncolytic virus, etc.) or has progressed after local treatment; 5. At least one measurable target lesion before preconditioning, as defined by RECIST1.1.
  4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  5. Patients must have an estimated life expectancy of ≥3 months. 8. Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function:
  6. Absolute Neutrophil Count (ANC)≥1.0×10\^9/L;
  7. Absolute Lymphocyte Count(ALC)≥0.5×10\^9/L;
  8. Platelet≥80×10\^9/L;
  9. International Normalized Ratio(INR)≤1.5×ULN;
  10. Activated Partial Thromboplastin Time(APTT)≤1.5×ULN;
  11. Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min
  12. Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g;
  13. Alanine aminotransferase(AST/SGOT) ≤3×ULN;
  14. Alanine aminotransferase (ALT/SGPT) ≤3×ULN;
  15. Total Bilirubin(TBIL)≤1.5×ULN; 9. Women of child-bearing potential (WCBP), must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.
  16. Patients must have no contraindications for surgery or biopsy. 11. Patients have good compliance and be able to adhere to research access plans and other protocol requirements.

排除标准:Exclusion Criteria:

  1. Participate in clinical trials of other drugs or biologic therapies within 4 weeks before enrollment;
  2. Participants who have had a history of allogeneic T cell therapy; gene engineering autologous cell therapy within 1 years.
  3. Patients who have received systemic antitumor therapy within 4 weeks.
  4. Patients who have had another primary malignancy within the previous 5 years
  5. Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
  6. Patients with a history of hypersensitivity to any component of the study drugs
  7. Patients who are pregnant or breastfeeding.

引自 ClinicalTrials.gov, NCT06375187, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06375187,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06375187